CN1302772C - Orally disintegrated sodium ferulate tablet and its prepn process - Google Patents
Orally disintegrated sodium ferulate tablet and its prepn process Download PDFInfo
- Publication number
- CN1302772C CN1302772C CNB2005100261411A CN200510026141A CN1302772C CN 1302772 C CN1302772 C CN 1302772C CN B2005100261411 A CNB2005100261411 A CN B2005100261411A CN 200510026141 A CN200510026141 A CN 200510026141A CN 1302772 C CN1302772 C CN 1302772C
- Authority
- CN
- China
- Prior art keywords
- sodium
- sodium ferulate
- agent
- filler
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NCTHNHPAQAVBEB-WGCWOXMQSA-M sodium ferulate Chemical compound [Na+].COC1=CC(\C=C\C([O-])=O)=CC=C1O NCTHNHPAQAVBEB-WGCWOXMQSA-M 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 239000000945 filler Substances 0.000 claims abstract description 15
- 238000004108 freeze drying Methods 0.000 claims abstract description 11
- 239000000314 lubricant Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 23
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 19
- 239000008101 lactose Substances 0.000 claims description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 19
- 108010011485 Aspartame Proteins 0.000 claims description 17
- 239000000605 aspartame Substances 0.000 claims description 17
- 235000010357 aspartame Nutrition 0.000 claims description 17
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 17
- 229960003438 aspartame Drugs 0.000 claims description 17
- 239000000796 flavoring agent Substances 0.000 claims description 14
- 235000013355 food flavoring agent Nutrition 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 239000000741 silica gel Substances 0.000 claims description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical group CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 7
- 239000007968 orange flavor Substances 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 238000007907 direct compression Methods 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000001530 fumaric acid Substances 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000003826 tablet Substances 0.000 abstract description 29
- 239000006191 orally-disintegrating tablet Substances 0.000 abstract description 25
- 238000004090 dissolution Methods 0.000 abstract description 14
- 238000005550 wet granulation Methods 0.000 abstract description 4
- 208000019505 Deglutition disease Diseases 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 238000009702 powder compression Methods 0.000 abstract 1
- 239000004576 sand Substances 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000007884 disintegrant Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 235000005979 Citrus limon Nutrition 0.000 description 5
- 244000131522 Citrus pyriformis Species 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 230000035597 cooling sensation Effects 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 229940109275 cyclamate Drugs 0.000 description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 229910002055 micronized silica Inorganic materials 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 241000167854 Bourreria succulenta Species 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000009740 moulding (composite fabrication) Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical group [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- -1 dry Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
技术领域Technical field
本发明涉及药物制剂技术领域,是一种阿魏酸钠口腔崩解片及其制备方法。The invention relates to the technical field of pharmaceutical preparations, and relates to a sodium ferulate orally disintegrating tablet and a preparation method thereof.
背景技术 Background technique
阿魏酸钠(sodium ferulate)是当归和川芎等中药提取物主要成分阿魏酸的钠盐,又称当归素或川芎素,主要用于冠心病、脑血管病、脉管炎及偏头痛等症的治疗。疗效确切,其上市口服剂型为普通片剂。但阿魏酸钠片在胃中难溶,按《中国药典》2005年版对阿魏酸钠片进行溶出度实验发现,市售阿魏酸钠片(成都亨达药业有限公司,批号040804)在人工胃液中45分钟仅溶出10%的药量,这影响药物体内吸收,药物起效缓慢。值得注意的是,阿魏酸钠片的临床使用对象多为需要长期用药的老年、卧床等特殊群体,这些患者往往会发生吞咽困难,药片很容易发生物理阻塞。最新的流行病学发现,仅普通老年患者就约有35%会发生吞药困难。Sodium ferulate (sodium ferulate) is the sodium salt of ferulic acid, the main component of traditional Chinese medicine extracts such as angelica and chuanxiong. disease treatment. The curative effect is definite, and its marketed oral dosage form is common tablet. However, sodium ferulate tablets are insoluble in the stomach. According to the dissolution test of sodium ferulate tablets in the 2005 edition of "Chinese Pharmacopoeia", it is found that commercially available sodium ferulate tablets (Chengdu Hengda Pharmaceutical Co., Ltd., batch number 040804) Only 10% of the drug dose is dissolved in the artificial gastric juice in 45 minutes, which affects the absorption of the drug in the body, and the drug takes effect slowly. It is worth noting that the clinical users of sodium ferulate tablets are mostly special groups such as the elderly and bedridden who need long-term medication. These patients often have difficulty swallowing, and the tablets are prone to physical blockage. According to the latest epidemiological findings, only about 35% of ordinary elderly patients will have difficulty swallowing medicine.
口腔崩解片是近十年来国外研究开发的一种新型固体制剂,指在口腔中不另用水或用很少的水,1分钟内能快速崩解或溶解的片剂。该剂型主要是选择崩解性能优良的崩解剂,药片置于患者舌上,遇唾液迅速溶解或崩解,药物借吞咽动作入胃起效。口腔崩解片与普通片剂相比,提供了一种新的服药方法,可方便患者用药,尤其适合老年人等吞咽困难患者用药,防止因片剂物理阻塞而窒息。同时,由于使用了崩解性能优良的崩解剂,片剂在口腔中迅速崩解,加快了药物溶出,使药物快速吸收并起效。但目前,尚未见有关阿魏酸钠口腔崩解片及其相关的研究报道。Orally disintegrating tablet is a new type of solid preparation researched and developed abroad in the past ten years. It refers to a tablet that can quickly disintegrate or dissolve within 1 minute in the oral cavity without additional water or with very little water. This dosage form mainly selects a disintegrant with excellent disintegration performance. The tablet is placed on the patient's tongue, and it dissolves or disintegrates quickly when it meets saliva, and the drug enters the stomach to take effect by swallowing. Compared with ordinary tablets, orally disintegrating tablets provide a new method of taking medicine, which is convenient for patients to take medicine, especially for the elderly and other patients with dysphagia, and prevents suffocation due to physical blockage of the tablet. At the same time, due to the use of a disintegrant with excellent disintegration performance, the tablet disintegrates rapidly in the oral cavity, which accelerates the dissolution of the drug and makes the drug quickly absorbed and effective. But at present, there is no relevant research report on sodium ferulate orally disintegrating tablets.
发明内容Contents of Invention
本发明提供一种吞咽方便、起效快的阿魏酸钠口腔崩解片及其制备方法。The invention provides an orally disintegrating sodium ferulate tablet which is convenient to swallow and has a quick effect and a preparation method thereof.
本发明的阿魏酸钠口腔崩解片,组分包括阿魏酸钠活性成分和药用可接受的辅料,阿魏酸钠的重量百分比为10~50%,辅料的重量百分比为50~90%,辅料包括崩解剂、填充剂,还可含有粘合剂、润滑剂、矫味剂。崩解剂的重量百分比为2~30%,填充剂的重量百分比为10~90%,粘合剂的重量百分比为1~5%,润滑剂的重量百分比不超过5%,矫味剂的重量百分比为0.1~20%。根据制备方法的不同,可选用相关辅料。The sodium ferulate orally disintegrating tablet of the present invention, the component comprises sodium ferulate active ingredient and pharmaceutically acceptable adjuvant, the weight percentage of sodium ferulate is 10-50%, the weight percentage of adjuvant is 50-90% %, auxiliary materials include disintegrants, fillers, and may also contain binders, lubricants, and flavoring agents. The weight percentage of the disintegrant is 2-30%, the weight percentage of the filler is 10-90%, the weight percentage of the binder is 1-5%, the weight percentage of the lubricant is not more than 5%, and the weight percentage of the flavoring agent The percentage is 0.1 to 20%. Depending on the preparation method, relevant auxiliary materials can be selected.
所述的崩解剂选自交联聚维酮、交联羧甲基纤维素钠、羧甲基淀粉钠、低取代羟丙基纤维素、微晶纤维素,可同时选用其中的一种或几种。The disintegrating agent is selected from crospovidone, croscarmellose sodium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, and one or more of them can be selected at the same time. Several kinds.
所述的填充剂选自乳糖、预胶化淀粉、甘露醇、山梨醇、木糖醇、赤藓糖醇,可同时选用其中的一种或几种。The filler is selected from lactose, pregelatinized starch, mannitol, sorbitol, xylitol, and erythritol, and one or more of them can be selected simultaneously.
所述的粘合剂选自糖浆、淀粉浆、羧甲基纤维素钠、羟丙基甲基纤维素、聚维酮,可同时选用其中的一种或几种。The binder is selected from syrup, starch slurry, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, povidone, and one or more of them can be selected simultaneously.
所述的润滑剂选自微粉硅胶、硬脂酸镁、滑石粉,可同时选用其中的一种或几种。Described lubricant is selected from micropowder silica gel, magnesium stearate, talcum powder, can select wherein one or more simultaneously.
所述的矫味剂包括甜味剂、香味剂和泡腾剂。甜味剂选自糖精钠、蔗糖、阿斯巴甜、甜蜜素,,可同时选用其中的一种或几种,重量百分比为1~5%;香味剂选自香草、樱桃、葡萄、桔子、柠檬、薄荷、蓝莓、香蕉、菠萝、水蜜桃、饴糖香精,重量百分比为0.1~1%;泡腾剂选自碳酸氢钠与酒石酸或柠檬酸或富马酸的混合物,重量百分比不超过15%。The flavoring agents include sweeteners, flavoring agents and effervescent agents. The sweetener is selected from sodium saccharin, sucrose, aspartame, and cyclamate, and one or more of them can be selected at the same time, and the weight percentage is 1 to 5%; the flavoring agent is selected from vanilla, cherry, grape, orange, Lemon, mint, blueberry, banana, pineapple, peach, caramel essence, the percentage by weight is 0.1-1%; effervescent agent is selected from the mixture of sodium bicarbonate and tartaric acid or citric acid or fumaric acid, the percentage by weight is not more than 15% .
阿魏酸钠口腔崩解片的制备方法可选用冷冻干燥法或粉末直接压片法或湿法制粒压片法。The preparation method of the sodium ferulate orally disintegrating tablet can be selected from a freeze-drying method, a powder direct compression method or a wet granulation tablet compression method.
1.冷冻干燥法:步骤是按配比将阿魏酸钠与崩解剂、填充剂、矫味剂混合均匀,加适量水稀释,充分混匀,置于相应片剂模具中,放入冻干机中冷冻干燥,至物料完全干燥成形。1. Freeze-drying method: the step is to mix sodium ferulate with disintegrant, filler, and flavoring agent according to the proportion, add appropriate amount of water to dilute, mix well, place in the corresponding tablet mold, and freeze-dry Freeze drying in the machine until the material is completely dry and shaped.
2.粉末直接压片法:步骤是按配比将阿魏酸钠、崩解剂、填充剂、矫味剂过筛,混合均匀,加入润滑剂混匀,直接压片成形。2. Powder direct compression method: the step is to sieve sodium ferulate, disintegrant, filler and flavoring agent according to the proportion, mix evenly, add lubricant and mix evenly, and directly compress into tablets.
3.湿法制粒压片法:步骤是按配比先将阿魏酸钠与填充剂、矫味剂及部分崩解剂混合均匀,加入粘合剂制成软材,制粒,烘干,整粒,最后加入剩余量崩解剂和润滑剂,压片成形。3. Wet granulation and tabletting method: the step is to mix sodium ferulate with filler, flavoring agent and part of disintegrating agent evenly according to the proportion, add binder to make soft material, granulate, dry, Granules, and finally add the remaining amount of disintegrant and lubricant, and compress into tablets.
经溶出度实验,本发明的口腔崩解片5分钟内阿魏酸钠溶出度大于90%,因而口服后药物起效快。本发明的口腔崩解片服用时不需用水,在口腔内仅依靠唾液1分钟内即崩解,对口腔粘膜没有刺激性,口感良好,酸度、甜度适宜,无沙砾感,特别适用于吞咽困难的老年患者。本发明的口腔崩解片制备方法简单,宜于工业化规模生产。According to the dissolution rate test, the dissolution rate of the sodium ferulate in the orally disintegrating tablet of the present invention is greater than 90% within 5 minutes, so the medicine takes effect quickly after oral administration. The orally disintegrating tablet of the present invention does not need water when taken, and disintegrates within 1 minute only by saliva in the oral cavity, has no irritation to the oral mucosa, has good taste, suitable acidity and sweetness, and has no gritty feeling, and is especially suitable for swallowing difficult elderly patients. The preparation method of the orally disintegrating tablet of the invention is simple and suitable for industrial scale production.
附图说明Description of drawings
图1为阿魏酸钠口腔崩解片与市售普通片在人工胃液中的溶出度曲线图Fig. 1 is the dissolution curve of sodium ferulate orally disintegrating tablets and commercially available common tablets in artificial gastric juice
图2为阿魏酸钠口腔崩解片与市售普通片在水中的溶出度曲线图Fig. 2 is the dissolution curve in water of sodium ferulate orally disintegrating tablets and commercially available common tablets
具体实施方式 Detailed ways
下面结合实施例及附图对本发明进行详细描述,但并不对本发明构成限制。The present invention will be described in detail below in conjunction with the embodiments and accompanying drawings, but the present invention is not limited thereto.
在具体实施时,根据需要及制备方法的不同,组分中可选用不同的辅料。In specific implementation, different auxiliary materials can be used in the components according to different requirements and preparation methods.
实施例1冷冻干燥法制备阿魏酸钠口腔崩解片Embodiment 1 freeze-drying method prepares sodium ferulate orally disintegrating tablet
组分及配比(w/w%)Components and ratio (w/w%)
阿魏酸钠 40Sodium Ferulate 40
羧甲基淀粉钠 5Sodium Carboxymethyl Starch 5
微晶纤维素 10
乳糖 23Lactose 23
蔗糖 20
阿斯巴甜 1.5Aspartame 1.5
橙子香精 0.5Orange flavor 0.5
制备方法:Preparation:
将阿魏酸钠与羧甲基淀粉钠、微晶纤维素、乳糖、蔗糖、阿斯巴甜、橙子香精,混悬于适量水中,搅拌1小时,制成混悬液,灌注于片剂模具中,进行冷冻干燥,冻干成形后压封,包装。Suspend sodium ferulate, sodium carboxymethyl starch, microcrystalline cellulose, lactose, sucrose, aspartame, and orange essence in appropriate amount of water, stir for 1 hour to make a suspension, and pour it into tablet molds , carry out freeze-drying, freeze-drying and forming, pressing and sealing, and packaging.
所得冻干制品结构疏松,置舌上酸度、甜度适宜,无沙砾感,崩解时间为5秒,100%溶出时间为4分钟。The resulting freeze-dried product has a loose structure, suitable acidity and sweetness on the tongue, no gritty feeling, a disintegration time of 5 seconds, and a 100% dissolution time of 4 minutes.
实施例2冷冻干燥法制备阿魏酸钠口腔崩解片Embodiment 2 freeze-drying method prepares sodium ferulate orally disintegrating tablet
组分及配比(w/w%)Components and ratio (w/w%)
阿魏酸钠 15Sodium Ferulate 15
低取代羟丙基纤维素 10Low-substituted
微晶纤维素 20
乳糖 33.8Lactose 33.8
预胶化淀粉 20
甜蜜素 1Cyclamate 1
樱桃香精 0.2Cherry flavor 0.2
制备方法:Preparation:
将阿魏酸钠与低取代羟丙基纤维素、微晶纤维素、乳糖、预胶化淀粉、甜蜜素、樱桃香精,混悬于适量水中,搅拌1小时,制成混悬液,灌注于片剂模具中,进行冷冻干燥,冻干成形后压封,包装。Suspend sodium ferulate, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, lactose, pregelatinized starch, cyclamate, and cherry essence in appropriate amount of water, stir for 1 hour to make a suspension, and pour it into In the tablet mold, freeze-drying is carried out, and after freeze-drying and molding, it is compressed and sealed, and packed.
所得冻干制品结构疏松,置舌上酸度、甜度适宜,无沙砾感,崩解时间为5秒,100%溶出时间为4分钟。The resulting freeze-dried product has a loose structure, suitable acidity and sweetness on the tongue, no gritty feeling, a disintegration time of 5 seconds, and a 100% dissolution time of 4 minutes.
实施例3粉末直接压片法制备阿魏酸钠口腔崩解片Embodiment 3 powder direct compression method prepares sodium ferulate orally disintegrating tablet
组分及配比(w/w%)Components and ratio (w/w%)
阿魏酸钠 25Sodium Ferulate 25
交联聚维酮 8Crospovidone 8
微晶纤维素 20
乳糖 19Lactose 19
甘露醇 23.5Mannitol 23.5
微粉硅胶 2Micropowder silica gel 2
硬脂酸镁 1Magnesium stearate 1
阿斯巴甜 1Aspartame 1
橙子香精 0.5Orange flavor 0.5
制备方法:Preparation:
将阿魏酸钠与交联聚维酮、微晶纤维素、乳糖、甘露醇过80目筛,与微粉硅胶、硬脂酸镁、阿斯巴甜、橙子香精等量递加混合均匀,直接压片成形,包装。Pass sodium ferulate, crospovidone, microcrystalline cellulose, lactose, and mannitol through an 80-mesh sieve, and mix them with micropowder silica gel, magnesium stearate, aspartame, and orange essence in equal amounts, and directly Tablet forming, packaging.
所得口腔崩解片置舌上有清凉感,酸度、甜度适宜,无沙砾感,崩解时间为47秒,100%溶出时间为10分钟,均符合药典规定。The obtained orally disintegrating tablet has a cooling sensation on the tongue, suitable acidity and sweetness, and no gritty feeling. The disintegration time is 47 seconds, and the 100% dissolution time is 10 minutes, all of which meet the requirements of the Pharmacopoeia.
实施例4粉末直接压片法制备阿魏酸钠口腔崩解片Embodiment 4 powder direct compression method prepares sodium ferulate orally disintegrating tablet
组分及配比(w/w%)Components and ratio (w/w%)
阿魏酸钠 22Sodium Ferulate 22
羧甲基淀粉钠 3Sodium Carboxymethyl Starch 3
微晶纤维素 18Microcrystalline Cellulose 18
乳糖 20
甘露醇 28Mannitol 28
碳酸氢钠 2Sodium bicarbonate 2
柠檬酸 2.5Citric acid 2.5
微粉硅胶 2Micropowder silica gel 2
硬脂酸镁 0.5Magnesium stearate 0.5
阿斯巴甜 1.5Aspartame 1.5
柠檬香精 0.5Lemon essence 0.5
制备方法:Preparation:
将阿魏酸钠与羧甲基淀粉钠、微晶纤维素、乳糖、甘露醇、碳酸氢钠、柠檬酸过80目筛,与微粉硅胶、硬脂酸镁、阿斯巴甜、柠檬香精等量递加混合均匀,直接压片成形,包装。Pass sodium ferulate, sodium carboxymethyl starch, microcrystalline cellulose, lactose, mannitol, sodium bicarbonate, citric acid through an 80-mesh sieve, and micronized silica gel, magnesium stearate, aspartame, lemon essence, etc. The amount is added and mixed evenly, directly compressed into tablets, and packaged.
所得口腔崩解片置舌上有泡腾、清凉感,酸度、甜度适宜,无沙砾感,崩解时间为32秒,100%溶出时间为8分钟,均符合药典规定。The obtained orally disintegrating tablet had effervescent and cooling sensations on the tongue, suitable acidity and sweetness, and no gritty feeling. The disintegration time was 32 seconds, and the 100% dissolution time was 8 minutes, all of which met the requirements of the Pharmacopoeia.
实施例5粉末直接压片法制备阿魏酸钠口腔崩解片
组分及配比(w/w%)Components and ratio (w/w%)
阿魏酸钠 30Sodium Ferulate 30
交联羧甲基纤维素钠 5
微晶纤维素 10
乳糖 11.5Lactose 11.5
甘露醇 28Mannitol 28
碳酸氢钠 5
酒石酸 6Tartaric acid 6
微粉硅胶 2Micropowder silica gel 2
硬脂酸镁 0.5Magnesium stearate 0.5
阿斯巴甜 1.5Aspartame 1.5
柠檬香精 0.5Lemon essence 0.5
制备方法:Preparation:
将阿魏酸钠与交联羧甲基纤维素钠、微晶纤维素、乳糖、甘露醇、碳酸氢钠、酒石酸过80目筛,与微粉硅胶、硬脂酸镁、阿斯巴甜、柠檬香精等量递加混合均匀,直接压片成形,包装。Pass sodium ferulate, croscarmellose sodium, microcrystalline cellulose, lactose, mannitol, sodium bicarbonate, and tartaric acid through an 80-mesh sieve, and mix with micronized silica gel, magnesium stearate, aspartame, and lemon The essence is added in equal amounts and mixed evenly, directly compressed into tablets and packaged.
所得口腔崩解片置舌上有泡腾、清凉感,酸度、甜度适宜,无沙砾感,崩解时间为30秒,100%溶出时间为8分钟,均符合药典规定。The obtained orally disintegrating tablet has an effervescent and cool feeling on the tongue, suitable acidity and sweetness, and no gritty feeling. The disintegration time is 30 seconds, and the 100% dissolution time is 8 minutes, all of which meet the requirements of the Pharmacopoeia.
实施例6湿法制粒压片法制备阿魏酸钠口腔崩解片Example 6 Preparation of Sodium Ferulate Orally Disintegrating Tablets by Wet Granulation and Tablet Compression
组分及配比(w/w%)Components and ratio (w/w%)
阿魏酸钠 30Sodium Ferulate 30
交联羧甲基纤维素钠 5
微晶纤维素 15
乳糖 10
甘露醇 30Mannitol 30
碳酸氢钠 2Sodium bicarbonate 2
富马酸 2.5Fumaric acid 2.5
微粉硅胶 2Micropowder silica gel 2
硬脂酸镁 2Magnesium stearate 2
阿斯巴甜 1Aspartame 1
橘子香精 0.5Orange flavor 0.5
制备方法:Preparation:
将阿魏酸钠与交联羧甲基纤维素钠、微晶纤维素、乳糖、甘露醇、碳酸氢钠、富马酸、微粉硅胶、阿斯巴甜混合均匀,用1%聚维酮乙醇溶液制粒,50℃烘干,整粒后喷入橘子香精,加入硬脂酸镁,压片成形,包装。Mix sodium ferulate with croscarmellose sodium, microcrystalline cellulose, lactose, mannitol, sodium bicarbonate, fumaric acid, micronized silica gel, aspartame, and use 1% povidone ethanol The solution is granulated, dried at 50°C, sprayed with orange essence after granulation, added with magnesium stearate, compressed into tablets, and packaged.
所得口腔崩解片置舌上有泡腾、清凉感,酸度、甜度适宜,无沙砾感,崩解时间为49秒,100%溶出时间为10分钟,均符合药典规定。The obtained orally disintegrating tablet had effervescent and cooling sensations on the tongue, suitable acidity and sweetness, and no gritty feeling. The disintegration time was 49 seconds, and the 100% dissolution time was 10 minutes, all of which met the requirements of the Pharmacopoeia.
将实施例3制得的口腔崩解片与市售阿魏酸钠片(成都亨达药业有限公司,批号040804)按《中国药典》2005年版分别进行人工胃液和水中的溶出度比较,结果见图1、图2。由图可见,本发明口腔崩解片在人工胃液和水中的溶出速率显著高于普通片。因而从体外实验表明,本发明口腔崩解片便于口服,且见效快。The orally disintegrating tablet that embodiment 3 makes is compared with the commercially available sodium ferulate tablet (Chengdu Hengda Pharmaceutical Co., Ltd., batch number 040804) by "Chinese Pharmacopoeia" 2005 edition, and the dissolution rate in artificial gastric juice and water is compared respectively, and the result See Figure 1 and Figure 2. It can be seen from the figure that the dissolution rate of the orally disintegrating tablet of the present invention in artificial gastric juice and water is significantly higher than that of the ordinary tablet. Therefore, in vitro experiments show that the orally disintegrating tablet of the present invention is convenient to take orally and has quick effect.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100261411A CN1302772C (en) | 2005-05-24 | 2005-05-24 | Orally disintegrated sodium ferulate tablet and its prepn process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100261411A CN1302772C (en) | 2005-05-24 | 2005-05-24 | Orally disintegrated sodium ferulate tablet and its prepn process |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1706372A CN1706372A (en) | 2005-12-14 |
CN1302772C true CN1302772C (en) | 2007-03-07 |
Family
ID=35580606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100261411A Expired - Fee Related CN1302772C (en) | 2005-05-24 | 2005-05-24 | Orally disintegrated sodium ferulate tablet and its prepn process |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1302772C (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100411621C (en) * | 2006-01-09 | 2008-08-20 | 深圳致君制药有限公司 | Cefixime oral disintegration tablet and its preparation method |
CN101077338B (en) * | 2006-05-24 | 2012-06-20 | 天津大学 | Nano lanthanum carbonate and orally disintegrating tablet and preparation method |
CN101138554B (en) * | 2006-09-05 | 2010-09-29 | 云南白药集团股份有限公司 | Effervescence dispersible tablet |
TWI468167B (en) * | 2007-11-16 | 2015-01-11 | 威佛(國際)股份有限公司 | Pharmaceutical composition |
CN103191069A (en) * | 2013-03-25 | 2013-07-10 | 海南卫康制药(潜山)有限公司 | Rapid disintegration tabella and chill-pressing method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1476826A (en) * | 2003-07-30 | 2004-02-25 | 北京中西经纬释药技术有限公司 | Oral disintegrant tablet and its preparation method |
CN1634014A (en) * | 2004-12-01 | 2005-07-06 | 北京科信必成医药科技发展有限公司 | Sodium ferulate oral disintegrating tablet and its preparation process |
-
2005
- 2005-05-24 CN CNB2005100261411A patent/CN1302772C/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1476826A (en) * | 2003-07-30 | 2004-02-25 | 北京中西经纬释药技术有限公司 | Oral disintegrant tablet and its preparation method |
CN1634014A (en) * | 2004-12-01 | 2005-07-06 | 北京科信必成医药科技发展有限公司 | Sodium ferulate oral disintegrating tablet and its preparation process |
Also Published As
Publication number | Publication date |
---|---|
CN1706372A (en) | 2005-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1222317C (en) | Quickly disintegrable compression-molded materials and process for producing the same | |
CN1239151C (en) | Tablets quickly disintegrating in oral cavity | |
CN1302772C (en) | Orally disintegrated sodium ferulate tablet and its prepn process | |
CN1233323C (en) | Orally disintegrating tablet of meloxicam and its preparation | |
JP2003176242A (en) | Quickly disintegrable compression-molded material and method for producing the same | |
CN100339081C (en) | Oral loratadine disintegrating tablet and its prepn | |
JP2007119453A (en) | Method for preventing lowering of bromhexine hydrochloride content | |
CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
CN1943561A (en) | Oral disintegration tablet of prulifloxacin and its preparing method | |
CN1506043A (en) | Quickly disintegrating tablet containing cadotril | |
JP2008127320A (en) | Solid preparation quickly disintegrating in oral cavity | |
CN1197556C (en) | Tablet disintegzated in mouth rapidly for preventing and curing vomit and preparing method | |
CN2745572Y (en) | Ring shaped Chinese medicine effervescent form | |
CN1582927A (en) | Oral disintegrants of nimodipine and their preparation | |
CN1237965C (en) | Oral disintegrating tablet of bambuterol hydrochloride and its preparation method | |
CN1297263C (en) | Calcium gluconate oral disintegrating tablet and its preparation process | |
CN1660098A (en) | Combination of tablet to swallow of containing Cetirizine Hydrochloride | |
CN1985807A (en) | Compound Desloratadine-Ambroxol oral disintegrated tablet and its preparing method | |
CN1562013A (en) | Nisoldipine oral disintegration tablet for treating hypertension and preparing method | |
CN1742956A (en) | Lonicera and Forsythia effervescent tablet for relieving internal heat or fever of humanbody | |
CN1429618A (en) | Erigeron breviscapus oral caving fast disintegration tablet and its preparation method | |
CN1562210A (en) | Burnet disintegration tablet of mouth and preparation method | |
CN1270721C (en) | Rapid disintegration and rapid dissolution tablet containing kakonein | |
CN1634082A (en) | Enteric coated orally disintegrating tablet of aspirin | |
CN1698665A (en) | Defervesce effervescence tablet for treating cold and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070307 |